The stock of Molecular Templates Inc. (NASDAQ:MTEM) last traded at $0.47, up 5.98% from the previous session.
Data from the available sources indicates that Molecular Templates Inc. (NASDAQ:MTEM) is covered by 5 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $18.00 and a low of $1.50, we find $10.50. Given the previous closing price of $0.44, this indicates a potential upside of 2286.36 percent. MTEM stock price is now -0.02% away from the 50-day moving average and -31.48% away from the 200-day moving average. The market capitalization of the company currently stands at $26.58M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
In total, 0 analysts have assigned it a hold rating, and 4 have given it a buy rating. Brokers who have rated the stock have averaged $10.13 as their price target over the next twelve months.
With the price target of $12, BofA Securities recently initiated with Buy rating for Molecular Templates Inc. (NASDAQ: MTEM). On February 01, 2021, UBS recently initiated its ‘Neutral’ rating on the stock quoting a target price of $13, while ‘Jefferies’ rates the stock as ‘Buy’.
In other news, McLennan Sean, insider bought 30,000 shares of the company’s stock on Jun 16. The stock was bought for $24,477 at an average price of $0.82. Upon completion of the transaction, the insider now directly owns 30,000 shares in the company, valued at $14100.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 15, 10% Owner SHV Management Services, LLC bought 62,000 shares of the business’s stock. A total of $55,180 was incurred on buying the stock at an average price of $0.89. This leaves the insider owning 222,000 shares of the company worth $0.1 million. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MTEM stock. A new stake in Molecular Templates Inc. shares was purchased by CREDIT SUISSE AG/ during the first quarter worth $482,000. JANE STREET GROUP, LLC invested $24,000 in shares of MTEM during the first quarter. In the first quarter, VIRTU FINANCIAL LLC acquired a new stake in Molecular Templates Inc. valued at approximately $12,000. TWO SIGMA SECURITIES, LLC acquired a new stake in MTEM for approximately $11,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP purchased a new stake in MTEM valued at around $6,000 in the second quarter. In total, there are 75 active investors with 74.50% ownership of the company’s stock.
With an opening price of $0.4400 on Thursday morning, Molecular Templates Inc. (NASDAQ: MTEM) set off the trading day. During the past 12 months, Molecular Templates Inc. has had a low of $0.31 and a high of $3.64. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.70, and a quick ratio of 1.70. The fifty day moving average price for MTEM is $0.4702 and a two-hundred day moving average price translates $0.6859 for the stock.
The latest earnings results from Molecular Templates Inc. (NASDAQ: MTEM) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.44, beating analysts’ expectations of -$0.48 by 0.04. This compares to -$0.54 EPS in the same period last year. The company reported revenue of $4.24 million for the quarter, compared to $2.38 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 78.23 percent. For the current quarter, analysts expect MTEM to generate $7.85M in revenue.
Molecular Templates Inc.(MTEM) Company Profile
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
